Vanda Pharmaceuticals | VNDA - Interest Expense On Debt


Vanda Pharmaceuticals reported -1.37B in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Akebia Therapeutics 362.52M 357.69M Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Anika Therapeutics 179.39M 556.84M Mar/2026
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
Eli Lilly USD 114.7M 134.3M Sep/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Esperion Therapeutics USD 22.64M 585K Dec/2025
Halozyme Therapeutics USD 5.51M 597K Mar/2026
Heron Therapeutics USD 600K 100K Dec/2024
Insmed USD 20.08M 517K Mar/2026
J&J USD 43M 25M Mar/2026
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Ligand Pharmaceuticals USD 1.78M 875K Dec/2025
Merck USD 479M 67M Mar/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 11.49B 36B Mar/2026
Novartis USD 281M 8M Sep/2025
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sanofi EUR 178M 203M Mar/2026
Takeda JPY 43.65B 79.98B Mar/2026
Teva Pharmaceutical Industries USD 216M 4M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Veracyte USD 2K 1000 Dec/2023